CER-628 – Statin / Niacin / Aspirin

CER-628 is being developed as a statin/niacin/aspirin follow-up compound to CER-627, the fixed-dose combination of niacin and aspirin.

The combination is expected to combine the attributes of CER-627 of enhancing HDL levels with reduced flushing, with the LDL-lowering properties of a statin.

This program is in preclinical development.